Avalon GloboCare, a clinical-stage global developer of cell-based technologies and therapeutics, established a strategic partnership with GE Healthcare. According to Avalon officials, the deal is designed to accelerate Avalon’s standardization, automation, and bioproduction for clinical-grade chimeric antigen receptor (CAR) T cells and other immune-effector cells for cellular immunotherapy, as well as exosomes/extracellular vesicles (EV)-based regenerative therapeutics.
Under this partnership, both Avalon and GE Healthcare will strategically establish automated and standardized GMP cell production capabilities. Avalon will be given access to GE Healthcare’s cell-processing expertise and products in the form of the FlexFactory Cell Therapy platform, FastTrak process development and training services, as well as extensive SOP and validation protocol library. Additionally, user training will be conducted both at GE Healthcare and on-site at Avalon’s Nanjing Epicon GMP facility with access to GE Healthcare’s biomanufacturing resources.
“In conjunction with Avalon’s clinical network in China, this strategic partnership will empower Avalon to improve manufacturing throughput and efficiency, alleviate cost burden, and minimize variability in the automated and standardized bio-production process of clinical-grade cellular products (such as CAR-T, CAR-NK, and stem cell-derived exosomes/EV), therefore, accelerating the development of Avalon’s clinical and commercialization programs in cellular medicines,” said David Jin, MD, PhD, president and CEO of Avalon GloboCare.
“This partnership enables Avalon to more fully leverage and integrate our core technology platforms and accelerate our clinical programs in cellular immunotherapy and stem cell-derived exosome-based regenerative therapeutics.”